{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:13:09Z","timestamp":1788955989945,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Human metapneumovirus (hMPV) is a major cause of acute lower respiratory tract infection in children, older adults, and individuals with underlying medical conditions. In pediatric populations, hMPV contributes substantially to hospitalizations, morbidity, and healthcare costs, yet no licensed vaccine or monoclonal antibody is currently available for prevention. This narrative review summarizes current evidence on emerging preventive strategies against hMPV, with particular emphasis on monoclonal antibodies (mAbs) and vaccines for children. Advances in structural virology have identified the fusion glycoprotein as the principal target of neutralizing immunity and have provided a rationale for the development of hMPV-specific and cross-reactive RSV\u2013hMPV mAbs. Several mAbs have shown potent neutralizing activity and protection in animal models, although clinical development remains limited. Vaccine development has progressed across multiple platforms, including live-attenuated, mRNA, protein-subunit, virus-like particle, and viral-vectored vaccines. However, key challenges remain, particularly regarding immunogenicity in seronegative infants, risk of enhanced respiratory disease, durability of protection, seasonality, and optimal target populations. Current evidence suggests that hMPV prevention in children will likely require a layered strategy combining maternal immunization, active vaccination during late infancy, and targeted protection for high-risk children beyond infancy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1932274","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:03:41Z","timestamp":1788955421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Human metapneumovirus prevention in children: emerging roles of monoclonal antibodies and vaccines"],"prefix":"10.3389","volume":"17","author":[{"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fainardi","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia Giorgia","family":"Arnesano","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Argentiero","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/89098","article-title":"A newly discovered human pneumovirus isolated from young children with respiratory tract disease","volume":"7","author":"van den Hoogen","year":"2001","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1204630","article-title":"Burden of human metapneumovirus infection in young children","volume":"368","author":"Edwards","year":"2013","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/v17081140","article-title":"Human metapneumovirus: a narrative review on emerging strategies for prevention and treatment","volume":"17","author":"Principi","year":"2025","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.100679","article-title":"The global burden of human metapneumovirus-associated acute respiratory infections in older adults: a systematic review and meta-analysis","volume":"6","author":"Kulkarni","year":"2025","journal-title":"Lancet Healthy Longev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piv027","article-title":"Incidence, morbidity, and costs of human metapneumovirus infection in hospitalized children","volume":"5","author":"Davis","year":"2016","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070717","article-title":"Challenges and limitations of current RSV prevention strategies in infants and young children: a narrative review","volume":"13","author":"Principi","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7411a1","article-title":"Human metapneumovirus seasonality and co-circulation with respiratory syncytial virus\u2014United States, 2014\u20132024","volume":"74","author":"Jobe","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf086","article-title":"Post-pandemic dynamics of the global circulation of human metapneumovirus and respiratory syncytial virus","volume":"232","author":"Billard","year":"2025","journal-title":"J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-070218","article-title":"Human metapneumovirus and respiratory syncytial virus in children: a comparative analysis","volume":"156","author":"Goldstein","year":"2025","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2026.108853","article-title":"Respiratory viral infections and disease severity in hospitalized children: a pre-immunoprophylaxis baseline study highlighting the role of human metapneumovirus","volume":"170","author":"Aykac","year":"2026","journal-title":"Int J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1435294","article-title":"Changes in the epidemiological patterns of respiratory syncytial virus and human metapneumovirus infection among pediatric patients and their correlation with severe cases","volume":"14","author":"Kuang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV virus taxonomy profile: Pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J Gen Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9939","DOI":"10.1038\/s41467-024-54287-x","article-title":"Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus","volume":"15","author":"Lee","year":"2024","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.chom.2023.07.002","article-title":"Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode","volume":"31","author":"Wen","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101337","article-title":"Structural basis for respiratory syncytial virus and human metapneumovirus neutralization","volume":"61","author":"Miller","year":"2023","journal-title":"Curr Opin Virol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16272","DOI":"10.2210\/pdb5u68\/pdb","article-title":"Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus","volume":"2","author":"Wen","year":"2017","journal-title":"Nat Microbiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/s41467-022-30205-x","article-title":"Profiling of hMPV F-specific antibodies isolated from human memory B cells","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(23)00134-9","article-title":"Neutralising antibodies against human metapneumovirus","volume":"4","author":"Guo","year":"2023","journal-title":"Lancet Microbe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83084-0","article-title":"Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains","volume":"88","author":"Herfst","year":"2007","journal-title":"J Gen Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature12442","article-title":"Cross-neutralization of four paramyxoviruses by a human monoclonal antibody","volume":"501","author":"Corti","year":"2013","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.immuni.2022.07.003","article-title":"Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein","volume":"55","author":"Rappazzo","year":"2022","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1101\/2025.06.09.657676","article-title":"Development of a potent monoclonal antibody for treatment of human metapneumovirus infections","volume":"17","author":"Harris","year":"2026","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1654304","article-title":"Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV\/hMPV cross-neutralizing epitopes","volume":"11","author":"Xiao","year":"2019","journal-title":"mAbs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01052-23","article-title":"Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface","volume":"97","author":"Xiao","year":"2023","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/2025.08.29.673069","article-title":"Structural basis for childhood antibody recognition of the human metapneumovirus fusion protein","volume":"17","author":"Khalil","year":"2025","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1086\/367901","article-title":"Human metapneumovirus infections in young and elderly adults","volume":"187","author":"Falsey","year":"2003","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00015-11","article-title":"Human metapneumovirus: lessons learned over the first decade","volume":"24","author":"Schildgen","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20456","article-title":"Prevalence and clinical characteristics of human metapneumovirus infections in hospitalized infants in Spain","volume":"41","author":"Garc\u00eda-Garc\u00eda","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"B29","unstructured":"About Human Metapneumovirus\n          \n          \n          Atlanta (GA\n          Centers for Disease Control and Prevention\n          \n          2026"},{"key":"B30","unstructured":"Human Metapneumovirus Infection: Questions and Answers\n          \n          \n          Geneva\n          World Health Organization\n          \n          2025"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1201\/b16778-33","article-title":"The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience","volume":"193","author":"Williams","year":"2006","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-5-200603070-00010","article-title":"Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients","volume":"144","author":"Englund","year":"2006","journal-title":"Ann Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu623","article-title":"Management of respiratory viral infections in hematopoietic cell transplant recipients","volume":"2","author":"Shah","year":"2012","journal-title":"Am J Blood Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1086\/509930","article-title":"Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients","volume":"44","author":"Boeckh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70257","article-title":"Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: an in-depth review of mechanisms of action, failure factors, and future perspectives","volume":"36","author":"Bizot","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.04.075","article-title":"Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged","volume":"25","author":"Yim","year":"2007","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00597","article-title":"Unveiling integrated functional pathways leading to enhanced respiratory disease associated with inactivated respiratory syncytial viral vaccine","volume":"10","author":"Russell","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38919-1_13","article-title":"Live-attenuated respiratory syncytial virus vaccines","volume":"372","author":"Karron","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.23.12877-12887.2004","article-title":"Recombinant human metapneumovirus lacking the SH, G, or M2-2 genes is attenuated and immunogenic in nonhuman primates","volume":"79","author":"Biacchesi","year":"2005","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/v5010192","article-title":"Breaking in: human metapneumovirus fusion and entry","volume":"5","author":"Cox","year":"2013","journal-title":"Viruses"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00692-26","article-title":"Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus","author":"Lamichhane","year":"2026","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.24.15114-15122.2005","article-title":"Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo","volume":"79","author":"Pham","year":"2005","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix006","article-title":"Evaluation of a live attenuated human metapneumovirus vaccine in adults and children","volume":"7","author":"Karron","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac206","article-title":"Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults","volume":"9","author":"August","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-064748","article-title":"Safety and immunogenicity of an mRNA-based hMPV\/PIV3 combination vaccine in seropositive children","volume":"153","author":"Schnyder Ghamloush","year":"2024","journal-title":"Pediatrics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2210\/pdb7sej\/pdb","article-title":"Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins","volume":"13","author":"Hsieh","year":"2022","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.10.009","article-title":"A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys","volume":"23","author":"Tang","year":"2005","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011584","article-title":"Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus","volume":"19","author":"Ou","year":"2023","journal-title":"PloS Pathog"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013312","article-title":"A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus","volume":"21","author":"Young","year":"2025","journal-title":"PloS Pathog"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00332-14","article-title":"Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model","volume":"88","author":"Cox","year":"2014","journal-title":"J Virol"},{"key":"B53","unstructured":"A Safety, Tolerability, and Immunogenicity Study of Mrna-1345 and Mrna-1365 in Participants Aged 5 Months to <24 Months\n          \n          \n          Bethesda (MD\n          National Library of Medicine (US\n          \n          2023"},{"key":"B54","unstructured":"Mrna Medicines We are Currently Developing\n          \n          \n          Cambridge (MA\n          Moderna, Inc\n          \n          2026"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.051","article-title":"Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice","volume":"31","author":"L\u00e9vy","year":"2013","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf160","article-title":"A randomized phase 1 clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-75 years of age","volume":"12","author":"Shapiro","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128345","article-title":"A phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age","volume":"77","author":"Davis","year":"2026","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155917","article-title":"A chimeric pneumovirus fusion protein carrying neutralizing epitopes of both MPV and RSV","volume":"11","author":"Wen","year":"2016","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708078","article-title":"Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses","volume":"10","author":"Olmedillas","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941865","article-title":"A pan-pneumovirus vaccine based on immunodominant epitopes of the fusion protein","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:03:43Z","timestamp":1788955423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2026.1932274"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932274","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1932274"}}